新药研发风险高,投入大,回报 周期 长,早已让药企砍管线成为常态。而近年来,出于资源配置和资金聚集的问题,医药企业的降本大刀更是频频挥向新药研发管线。近期,辉瑞、渤健、礼来等跨国制药巨头就已相继终止了多款高价新药的开发。近日,有报道称,辉瑞在宣布将终止B型血友病基因疗法Beqvez的开发和商业化。这款定价高达350万美元的基因疗法,从获批到被放弃,仅仅过了一年的时间。公开资料显示,该疗法的研发始于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.